BCR is unreliable surrogate for overall survival in prostate cancerSeptember 7, 2023Genitourinary CancerOncologyProstate Cancer
Predicting prostate cancer risk: Are polygenic risk scores ready for prime time?September 6, 2023Genitourinary CancerProstate Cancer
Improving Germline Genetic Testing Among Veterans With High Risk, Very High Risk and Metastatic Prostate CancerSeptember 6, 2023OncologyHematologyGenitourinary CancerProstate Cancer
Do AI chatbots give reliable answers on cancer? Yes and noSeptember 1, 2023Breast CancerLung CancerGenitourinary CancerMelanomaProstate Cancer
Race and Age-Related PSA Testing Disparities in Spinal Cord Injured Men: Analysis of National Veterans Health Administration DataAugust 15, 2023Prostate Cancer
FDA OKs combo therapy of niraparib, abiraterone acetate for prostate cancerAugust 14, 2023Genitourinary CancerProstate Cancer
MRI-guided SBRT cuts radiation toxicity in prostate cancerJuly 26, 2023Genitourinary CancerProstate Cancer
‘Treatment holiday’ in prostate cancer with tailored dosingJuly 25, 2023Genitourinary CancerProstate Cancer
Cancer Data Trends 2023July 5, 2023Breast CancerGenitourinary CancerLung CancerProstate CancerColon and RectalMelanoma
Risk of falls seen with newer antiandrogens for prostate cancerJune 9, 2023Genitourinary CancerProstate Cancer
Prostate cancer subgroup may benefit from intensified therapyMarch 1, 2023Genitourinary CancerProstate CancerOncology
Talazoparib add-on improves outcomes in metastatic prostate cancerFebruary 22, 2023Genitourinary CancerProstate Cancer
